In July 2013, OptiNose licensed exclusive North American rights for the commercialization and further development of AVP-825 to Avanir Pharmaceuticals. Per the arrangement, OptiNose will transfer the U.S. IND for AVP-825 to Avanir, and Avanir will assume responsibility for the final filing of the U.S. NDA and for North American commercial manufacturing and sales.
Other Partnerships and Technology Licenses
Although focused on development of its own proprietary new treatments, OptiNose has allowed use of its technology by a small number of academic researchers, and entered into technology licensing arrangements with carefully selected companies developing their own products that may benefit greatly from this unique type of drug delivery. If your research may benefit from the use of the unique OptiNose delivery technology, please call or contact us using the link below.
Please contact us at email@example.com if your company is interested in exploring partnership opportunities for an innovative, non-oral or non-injected delivery platform for your proprietary CNS, systemic or topical nasal compounds.